Valbenazine

Valbenazine
Clinical data
Trade namesIngrezza
Other namesNBI-98854
AHFS/Drugs.comMonograph
MedlinePlusa617023
License data
Routes of
administration
By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding>99%
MetabolismActivation by hydrolysis, deactivation by CYP3A, CYP2D6
Metabolites[+]-α-Dihydrotetrabenazine (active metabolite)
Elimination half-life15–22 hrs
Excretion60% urine, 30% faeces
Identifiers
  • (2R,3R,11bR)-3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl L-valinate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.236.234 Edit this at Wikidata
Chemical and physical data
FormulaC24H38N2O4
Molar mass418.578 g·mol−1
3D model (JSmol)
  • CC(C)C[C@@H]1CN2CCc3cc(c(cc3[C@H]2C[C@H]1OC(=O)[C@H](C(C)C)N)OC)OC
  • InChI=InChI=1S/C24H38N2O4/c1-14(2)9-17-13-26-8-7-16-10-21(28-5)22(29-6)11-18(16)19(26)12-20(17)30-24(27)23(25)15(3)4/h10-11,14-15,17,19-20,23H,7-9,12-13,25H2,1-6H3/t17-,19-,20-,23+/m1/s1
  • Key:GEJDGVNQKABXKG-CFKGEZKQSA-N

Valbenazine, sold under the brand name Ingrezza, is a medication used to treat tardive dyskinesia.[1] It acts as a vesicular monoamine transporter 2 (VMAT2) inhibitor.[2]

  1. ^ a b "Ingrezza- valbenazine capsule; Ingrezza- valbenazine kit". DailyMed. 18 August 2023. Retrieved 17 November 2023.
  2. ^ O'Brien CF, Jimenez R, Hauser RA, Factor SA, Burke J, Mandri D, et al. (October 2015). "NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study". Movement Disorders. 30 (12): 1681–7. doi:10.1002/mds.26330. PMC 5049616. PMID 26346941.